ethyl 4-(4-hydroxyphenyl)-2,2-dimethyl-4-oxobutanoate | 1224582-91-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: ethyl 4-(4-hydroxyphenyl)-2,2-dimethyl-4-oxobutanoate
• CAS: 1224582-91-5
• 化学式: C₁₄H₁₈O₄
• 分子量: 250.295
• InChiKey: ZXFNAUGTFMVJSV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 4-(4-hydroxyphenyl)-2,2-dimethyl-4-oxobutanoate 在 sodium cyanoborohydride 、 三苯基膦 、 三氟乙酸 、 肼 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 溶剂黄146 、 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 生成 6-[4-(1-cyclobutyl-piperidin-4-yloxy)phenyl]-4,4-dimethyl-4,5-dihydro-2H-pyridazin-3-one
  参考文献：
  名称：

  4-Phenoxypiperidine pyridazin-3-one histamine H3 receptor inverse agonists demonstrating potent and robust wake promoting activity

  摘要：

  Structure-activity relationships for a series of phenoxypiperidine pyridazin-3-one H3R antagonists/inverse agonists are disclosed. The search for compounds with improved hERG and DAT selectivity without the formation of in vivo active metabolites identified 6-[4-(1-cyclobutyl-piperidin-4-yloxy)phenyl]- 4,4-dimethyl-4,5-dihydro-2H-pyridazin-3-one 17b. Compound 17b met discovery flow criteria, demonstrated potent H3R functional antagonism in vivo in the rat dipsogenia model and potent wake activity in the rat EEG/EMG model at doses as low as 0.1 mg/kg ip. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.01.026
• 作为产物：
  描述：

  2,2-二甲基琥珀酸酐 在 硫酸 、 氢溴酸 作用下， 以 四氢呋喃 为溶剂， 生成 ethyl 4-(4-hydroxyphenyl)-2,2-dimethyl-4-oxobutanoate
  参考文献：
  名称：

  4,5-Dihydropyridazin-3-one derivatives as histamine H3 receptor inverse agonists

  摘要：

  H3R structure-activity relationships for a new class of 4,5-dihydropyridazin-3-one H3R antagonists/inverse agonists are disclosed. Modification of the 4,5-dihydropyridazinone moiety to block in vivo metabolism identified 4,4-dimethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one 22 as a lead candidate demonstrating potent in vivo functional H3R antagonism in the rat dipsogenia model and robust wake promoting activity in the rat EEG/EMG model. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.11.037

文献信息

• Pyridizinone derivatives
  申请人：Hudkins L. Robert

  公开号：US20080027041A1

  公开（公告）日：2008-01-31

  The present invention provides compounds of formula (I*): their use as H 3 inhibitors, processes for their preparation, and pharmaceutical compositions thereof.

  本发明提供了式(I*)的化合物：它们作为H3抑制剂的用途，其制备方法以及药物组合物。
• Direct α‐Tertiary Alkylations of Ketones in a Combined Copper–Organocatalyst System
  作者：Ayako Kurose、Yuto Ishida、Goki Hirata、Takashi Nishikata

  DOI：10.1002/anie.202016051

  日期：2021.5.3

  Herein, we report an efficient method for the tertiary alkylation of a ketone by using an α‐bromocarbonyl compound as the tertiary alkyl source in a combined Cu‐organocatalyst system. This dual catalyst system enables the addition of a tertiary alkyl radical to an enamine. Mechanistic studies revealed that the catalytically generated enamine is a key intermediate in the catalytic cycle. The developed

  在本文中，我们报告了一种有效的方法，通过在复合有机铜催化剂体系中使用α-溴羰基化合物作为叔烷基源，可以使酮进行叔烷基化。这种双重催化剂体系能够将叔烷基加成到烯胺上。机理研究表明，催化生成的烯胺是催化循环中的关键中间体。所开发的方法可用于合成取代的1,4-二羰基化合物，这些化合物包含带有各种烷基链的季碳。
• Copper-Catalyzed Alkylation of Silyl Enol Ethers with Sterically Hindered α-Bromocarbonyls: Access to the Histamine H₃ Receptor Antagonist
  作者：Dengke Li

  DOI：10.1021/acs.joc.0c02277

  日期：2021.1.1

  A general and efficient copper-catalyzed alkylation of silyl enol ethers with functionalized alkyl bromides has been developed for the synthesis of the sterically hindered γ-ketoesters. The transformation was induced through C(sp3)-halogen activation of commercially available sterically hindered alkyl bromides under mild conditions in good results. The strategy could be used for the synthesis of biologically

  已经开发了一种通用且有效的铜催化的甲硅烷基烯醇醚与官能化的烷基溴化物的烷基化反应，用于合成位阻γ-酮酸酯。在温和的条件下，通过C（sp 3）-卤素活化市售的位阻烷基溴化物可诱导转化，效果良好。该策略可用于合成具有药用活性的生物活性组胺H 3受体（H 3 R）拮抗剂。
• Pyridazinone Derivatives
  申请人：Bacon Edward R.

  公开号：US20110288075A1

  公开（公告）日：2011-11-24

  The present invention is directed to novel pyridazinone derivatives that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition/cognitive disorders.

  本发明涉及新型吡啶并咪唑酮衍生物，可介导酶活性。特别是，这些化合物可能在治疗与组胺H3受体活性相关的疾病或疾病状态方面具有有效性，包括神经退行性疾病、睡眠/清醒障碍、注意力缺陷多动障碍和认知/认知障碍等。
• PYRIDAZINONE DERIVATIVES
  申请人：Bacon Edward R.

  公开号：US20140142088A1

  公开（公告）日：2014-05-22

  The present invention is directed to novel pyridazinone derivatives that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition.

  本发明涉及新型吡啶酮衍生物，可介导酶活性。特别地，这些化合物可能在治疗与组胺H3受体活性相关的疾病或疾病状态方面具有有效性，包括但不限于神经退行性疾病、睡眠/觉醒障碍、注意力缺陷多动障碍和认知方面。